<DOC>
	<DOCNO>NCT01069874</DOCNO>
	<brief_summary>Purpose : The study null hypothesis vitamin D supplementation influence time acute respiratory tract infection shelter accommodation resident .</brief_summary>
	<brief_title>Trial Vitamin D Supplementation Prevention Influenza Other Respiratory Infections ( ViDiFlu )</brief_title>
	<detailed_description>The study population comprise shelter accommodation resident staff fulfil eligibility criterion . Half shelter accommodation scheme randomly allocate 2-monthly oral bolus vitamin D supplementation ( Vigantol oil ) period one year , half placebo . Participants follow one year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<criteria>Permanent resident member staff shelter accommodation unit If woman childbearing potential , sexually abstinent negative pregnancy test within 7 day recruitment agree use reliable form contraception complete study Able give write informed consent participate Age â‰¥ 16 year day first dose IMP Current diagnosis asthma chronic obstructive pulmonary disease Chronic upper low respiratory infection condition cause chronic cough Condition require treatment vitamin D dose &gt; 10 microgram vitamin D/day Episode upper low respiratory tract infection 28 day first dose IMP Known sarcoidosis , hyperparathyroidism , nephrolithiasis , active tuberculosis , vitamin D intolerance , liver failure , renal failure , terminal illness , lymphoma malignancy remission time recruitment Taking benzothiadiazine derivative , cardiac glycoside , carbamazepine , phenobarbital , phenytoin , primidone longterm immunosuppressant therapy Taking oral preparation contain &gt; 10 microgram vitamin D/day 2 month first dose IMP Using topical vitamin D analogue Treatment investigational medical product device 4 month first dose IMP Breastfeeding , pregnant planning pregnancy Baseline correct serum calcium &gt; 2.65 mmol/L Baseline serum creatinine &gt; 125 micromol/L Inability complete symptom diary / without assistance Cognitive impairment communication problem precluding inform consent successful completion study evaluation</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Bone Density Conservation Agents</keyword>
	<keyword>Cholecalciferol</keyword>
	<keyword>Communicable Diseases</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Housing Elderly</keyword>
	<keyword>Infection</keyword>
	<keyword>Micronutrients</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Vitamins</keyword>
	<keyword>Respiratory Tract Infections/prevention &amp; control*</keyword>
	<keyword>Vitamin D</keyword>
</DOC>